Bridging aging and colorectal cancer: Synergistic roles of inflammaging and immunosenescence - Report - MDSpire

Bridging aging and colorectal cancer: Synergistic roles of inflammaging and immunosenescence

  • By

  • Zaongo, Silvere D

  • Yang, Qiyu

  • Han, Mei

  • Xi, Tianlan

  • Luo, Zilang

  • Wang, Xin

  • Yang, Jiadan

  • Ouyang, Jing

  • May 12, 2026

  • 0 min

Share

Clinical Report: Connecting Aging and Colorectal Cancer: The Interplay of Inflammaging and Immunosenescence

Overview

This report highlights the significant role of aging as a risk factor for colorectal cancer (CRC), emphasizing the interconnected processes of inflammaging and immunosenescence. These mechanisms contribute to a tumor-promoting environment and reduced immune surveillance, increasing susceptibility to CRC in older adults.

Background

Colorectal cancer is a leading cause of cancer-related morbidity and mortality, particularly among older adults. Understanding the immunological mechanisms, such as inflammaging and immunosenescence, that underlie the increased risk of CRC in this population is crucial for developing effective prevention and treatment strategies. The interplay of these processes may inform future research and clinical practices aimed at reducing CRC burden in aging populations.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Aging is a key risk factor for colorectal cancer, with incidence and mortality rates rising sharply in older adults.
  • Inflammaging is characterized by chronic low-grade inflammation, which promotes a tumor-friendly microenvironment.
  • Immunosenescence leads to diminished immune surveillance, reducing the clearance of premalignant cells.
  • Both processes contribute to genomic instability and persistent cytokine activation, predisposing the aging colon to malignant transformation.
  • Insights into these mechanisms may guide future biomarker discovery and therapeutic interventions.

Clinical Implications

Healthcare professionals should consider the roles of inflammaging and immunosenescence when assessing CRC risk in older patients. Integrating knowledge of these processes into screening and treatment plans may enhance patient outcomes and inform personalized care strategies.

Conclusion

The interplay of inflammaging and immunosenescence is critical in understanding the increased risk of colorectal cancer in older adults. Addressing these factors may lead to improved prevention and treatment approaches for this vulnerable population.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Immunosenescence as a Driver of the Transition from Frailty to Multimorbidity
  2. Chronic Inflammation and Its Connection to Colitis and Cancer in Inflammatory Bowel Disease, 2024
  3. Journal of Crohn's and Colitis -- Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer
  4. Recommendation: Colorectal Cancer: Screening | United States Preventive Services Taskforce
  5. Geriatric Assessment: ASCO Global Guideline - PubMed
  6. Ageing, immune fitness and cancer | Nature Reviews Cancer
  7. the pathologist — When Inflammation Fuels Cancer in the IBD Colon
  8. Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
  9. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
  10. Recommendation: Colorectal Cancer: Screening | United States Preventive Services Taskforce
  11. Geriatric Assessment: ASCO Global Guideline - PubMed
  12. Ageing, immune fitness and cancer | Nature Reviews Cancer
  13. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
  14. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial - PubMed
  15. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). | Journal of Clinical Oncology
  16. Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026 | OncLive
  17. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - PubMed
  18. Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis | World Journal of Surgical Oncology | Springer Nature Link

Original Source(s)

Related Content